How FDA scientists opposed the Trump administration’s push for easier access to peptides

A plan to give Americans easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with the policy’s development. The document, which covers certain injectable peptides popular within the wellness industry, recently underwent regulatory review at the White House, typically the final step before publicati...